News 2017

OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

Taipei, Taiwan, December 22, 2017 6:00pm – OBI Pharma, Inc. (TPEx:4174), a Taiwan biopharma company specializing in the development of novel first-in-class cancer therapeutics that uniquely target Globo Series (including …

OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Study finds OBI-3424 exerts profound in vivo efficacy and safety against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) expressing AKR1C3. Taipei, Taiwan, October 29, 2017 – OBI …

OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Poster presentation to reveal data regarding in vivo efficacy against patient-derived xenografts (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) Taipei, Taiwan, October 24, 2017 — OBI Pharma, Inc., a …

Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)

OBI Pharma (‘OBI’, TPEx: 4174) has signed a licensing agreement and a master services and clinical supply agreement with Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group), a UK-based life …

OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals

OBI Pharma to develop OBI-3424 (previously TH-3424) as a potential treatment of cancers expressing AKR1C3. Taipei, Taiwan, June 1, 2017 — OBI Pharma, Inc., a Taiwan biopharma company (TPex: 4174), …

China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study

On 24 January 2017, OBI Pharma, Inc. (4174) received formal approval from the China Food and Drug Administration (CFDA) to conduct a proposed phase III clinical trial for Adagloxad Simolenin …

OBI Pharma holds EOP2 meeting with US FDA

OBI Pharma, Inc. has met with the Office of Tissues and Advanced Therapies (OTAT) of the US Food and Drug Administration (FDA) for its End-of-Phase 2 (EOP2) meeting for Adagloxad …

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence. Shi-Lin District prosecutors Office announced today (9 Jan 2017) the result of the investigation of …